Author: Anna Smith

The deal makes the platform available for application in Juno’s CAR-T and TCR-T programmes in oncology and other indications.

Data from the Phase III CASPIAN trial has shown that the addition of tremelimumab to Imfinzi did not significantly improve overall survival.

On the other hand, the gefapixant 15mg twice daily treatment arms did not meet the primary efficacy endpoint.

As the case count for COVID-19 (coronavirus) in the UK hits 1950, pharma companies continue to pitch in with their efforts.